Silo Pharma Inc (SILO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Silo Pharma Inc (SILO) has a cash flow conversion efficiency ratio of -0.145x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-822.62K) by net assets ($5.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Silo Pharma Inc net asset quality index to measure how much of total assets are equity-financed.
Silo Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Silo Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Silo Pharma Inc (SILO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Silo Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Silo Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Novakand Pharma AB (publ)
ST:LARK
|
-0.029x |
|
Mha Ltd
LSE:MHA
|
N/A |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
-0.056x |
|
Helios Energy Ltd
AU:HE8
|
-0.020x |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
-0.055x |
|
KST Beteiligungs AG
F:KSW
|
N/A |
|
Terrain Minerals Ltd
AU:TMX
|
-0.113x |
|
Big Tree Cloud Holdings Limited Ordinary Shares
NASDAQ:DSY
|
-0.225x |
Annual Cash Flow Conversion Efficiency for Silo Pharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Silo Pharma Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see SILO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-4.66 Million | -0.739x | +2.93% |
| 2024-12-31 | $5.03 Million | $-3.83 Million | -0.762x | -45.89% |
| 2023-12-31 | $6.18 Million | $-3.22 Million | -0.522x | -54.34% |
| 2022-12-31 | $10.34 Million | $-3.50 Million | -0.338x | -34.55% |
| 2021-12-31 | $9.06 Million | $-2.28 Million | -0.251x | +72.18% |
| 2020-12-31 | $1.28 Million | $-1.16 Million | -0.903x | -102.60% |
| 2019-12-31 | $-22.89K | $-794.32K | 34.699x | +5085.55% |
| 2018-12-31 | $407.44K | $272.64K | 0.669x | +382.84% |
| 2017-12-31 | $1.20 Million | $-284.62K | -0.237x | -39.51% |
| 2016-12-31 | $846.51K | $-143.56K | -0.170x | +67.32% |
| 2015-12-31 | $1.96 Million | $-1.02 Million | -0.519x | -15.64% |
| 2014-12-31 | $2.37 Million | $-1.06 Million | -0.449x | -341.92% |
| 2013-12-31 | $1.79 Million | $-181.61K | -0.102x | -119.48% |
| 2012-12-31 | $-41.19K | $-21.47K | 0.521x | -98.03% |
| 2011-12-31 | $-1.75K | $-46.30K | 26.489x | -- |
About Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's … Read more